Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 23,577 Repligen Corporation $RGEN

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, Holdings Channel reports. The firm acquired 23,577 shares of the biotechnology company’s stock, valued at approximately $3,217,000.

A number of other institutional investors and hedge funds have also made changes to their positions in RGEN. AQR Capital Management LLC purchased a new position in Repligen in the first quarter worth approximately $262,000. Jones Financial Companies Lllp increased its position in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after purchasing an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after purchasing an additional 20,375 shares during the last quarter. Bank of Nova Scotia raised its holdings in shares of Repligen by 88.0% in the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after purchasing an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in shares of Repligen by 29.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after purchasing an additional 7,148 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. JPMorgan Chase & Co. lifted their price target on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Royal Bank Of Canada started coverage on Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Finally, HSBC dropped their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $166.43.

Insider Activity at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.60% of the company’s stock.

Repligen Trading Down 3.2%

NASDAQ RGEN opened at $176.27 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The firm’s fifty day moving average price is $151.99 and its 200 day moving average price is $133.09. The company has a market capitalization of $9.95 billion, a price-to-earnings ratio of 241.47, a price-to-earnings-growth ratio of 3.32 and a beta of 1.03. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $188.73.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. During the same period in the previous year, the company earned $0.26 earnings per share. Repligen’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts expect that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.